drugset / Trial / NCT00022880

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

NCT00022880

Phase 1 Unknown 30 enrolled Corixa Corporation GlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody, to see what effects it has on patients with CLL and to determine the highest dose of Iodine-131 Anti-B1 Antibody that can be given without causing severe side effects.

Timeline

Start
1999-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject TOSITUMOMAB 131I Monoclonal antibody 35 unknown